Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cemiplimab + carboplatin + pemetrexed
- Development stage
- Unknown
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
**cemiplimab + carboplatin + pemetrexed** is a combination regimen used as first-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) in patients not suitable for curative surgery or definitive chemoradiation. Cemiplimab is a monoclonal antibody that blocks the programmed cell death protein 1 (PD-1), restoring T-cell mediated immune response against cancer cells. Carboplatin is a small molecule platinum-based chemotherapy agent causing DNA crosslinking and apoptosis, and pemetrexed is a small molecule antifolate that inhibits folate-dependent enzymes in purine and pyrimidine synthesis, leading to cell death. This regimen improves survival and is generally well tolerated, as shown in randomized phase III trials.
- Other names
- cemiplimab + carboplatin + pemetrexedCRBPPEME+CEMI Regimen
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)DHFR (Dihydrofolate reductase)DNAGART (GAR transformylase)
Beyond the preview
Go deeper on cemiplimab + carboplatin + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cemiplimab + carboplatin + pemetrexed.